

AML Hub continues to enhance global knowledge of acute myeloid leukemia throughout 2021

Monday 18 October, 2021

Press Release: Available for Immediate Release

The [AML Hub](#), run by [Scientific Education Support \(SES\)](#) in partnership with the [European LeukemiaNet \(ELN\)](#), has continued to promote significant developments in the treatment and research of acute myeloid leukemia (AML) throughout Quarter 3 of 2021. The AML Hub provides up-to-date, unbiased material for healthcare professionals within the AML community, worldwide.

Speaking about the impact the hub has had this year, Mia Hill, IME Director at Scientific Education Support, said:

“The AML Hub virtually attended two key congresses in Q3: the 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) and the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH). We provided live social media updates from these congresses, summarizing key talks relating to the latest therapeutic approaches and diagnosis of AML. Our coverage generated over 64,000 impressions on our social channels, which resulted in over 900 website users for the hub. Additionally, we will produce articles on key research presented at the 3rd NCRI AML academy, which took place in September.”

The AML Hub owes thanks to its supporters—Roche Genentech, AbbVie, Amgen, Novartis, Bristol Myers Squibb, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Gamida Cell, and Takeda —without whom the work would not be possible. In Quarter 3, the AML Hub was delighted to welcome Pfizer as a supporter and would like to extend a special thanks for their support going forward.

ENDS

For more information on the AML Hub, please visit aml-hub.com.

For media enquiries or to explore collaboration opportunities, please contact barry.connolly@scientificeducationsupport.com or secretariat@scientificeducationsupport.com.

About acute myeloid leukemia (AML)

AML is a form of blood cancer originating in the bone marrow and is caused by an uncontrolled expansion of immature stem cells of myeloid lineage. It is the most common acute leukemia in adults and increases in incidence with age.

Understanding the molecular changes associated with the progression of AML has led to risk stratification and promising new targeted therapies. However, the only potentially curative option is allogeneic hematopoietic stem cell transplantation, which has become more readily available and safer owing to reduced-intensity conditioning regimens.

About the AML Hub

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in AML. Our aim is to enhance knowledge of AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The AML Hub enables time-stretched HCPs to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, the AML Hub supports HCPs worldwide.

The AML Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

AML Hub supporters

Funding for our hubs is made possible through financial support from the pharmaceutical industry. ?All

Related Sectors:

Medical & Pharmaceutical ::

Related Keywords:

Acute :: Myeloid :: Leukemia ::

Scan Me:



content is developed by SES in collaboration with an expert steering committee. ?All content is independent, and the educational supporters are allowed no influence on the content.?

- Pfizer
- Genentech
- Roche
- AbbVie
- Amgen
- Novartis
- Bristol Myers Squibb
- Syndax
- Janssen Oncology
- Jazz Pharmaceuticals
- Gamida Cell
- Takeda

If you are interested in becoming an AML supporter, please contact secretariat@scientificeducationsupport.com.

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'Know' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, including the [ALL Hub](#), [GvHD Hub](#), [Lymphoma Hub](#), [MDS Hub](#), [Multiple Myeloma Hub](#), and [MPN Hub](#).

About the European LeukemiaNet

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SMEs across Europe to form a network promoting cooperative research for curing leukemia.

Company Contact:

Scientific Education Support

E. [Abbie.Gunn@scientificeducationsupport...](mailto:Abbie.Gunn@scientificeducationsupport.co.uk)

W. [https://www.scientificeducationsuppor...](https://www.scientificeducationsupport.co.uk)

View Online

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.scientific-education-support.pressat.co.uk>